Search results for "Inflammation."

showing 10 items of 2627 documents

Antioxidant treatment for impaired hypoxic ventilatory responses in experimental diabetes in the rat

2018

Inflammation, tissue hypoxia, and impaired hypoxic ventilatory response (HVR) are the intricately entwined features of diabetes which perpetuate the disease and its sequelae. Hyperglycemia, notably, is an oxygen consuming process due to enhanced cellular metabolism. Oxidative stress underlies diabetic pathogenesis and also is a crucial modulator of the hypoxic chemoreflex. The present study seeks to determine if suppressed ventilation in diabetes could be improved by antioxidant treatment. The study was performed in streptozotocin-induced diabetes in awake rats. Two weeks into full-fledged diabetes, the rats were divided into mangiferin (potent natural antioxidant)-treated and untreated, wi…

Blood GlucoseMale0301 basic medicinePulmonary and Respiratory MedicineAntioxidantPhysiologyXanthonesmedicine.medical_treatmentInflammationHypoxic ventilatory responsePharmacologymedicine.disease_causeThiobarbituric Acid Reactive SubstancesAntioxidantsDiabetes Mellitus ExperimentalSuperoxide dismutase03 medical and health scienceschemistry.chemical_compoundAntioxidant treatment; Diabetes; Hypoxic ventilatory response; Inflammation; Mangiferin; Oxidative stress.Diabetes mellitusmedicineAnimalsRats WistarHypoxiaMangiferinInflammationbiologySuperoxide DismutaseTumor Necrosis Factor-alphabusiness.industryRespirationGeneral NeuroscienceBrainmedicine.diseaseOxidative Stress030104 developmental biologychemistrybiology.proteinTumor necrosis factor alphaLipid Peroxidationmedicine.symptombusinessOxidative stressRespiratory Physiology & Neurobiology
researchProduct

Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance

2017

Low-grade inflammation links obesity to insulin resistance through the activation of tissue-infiltrating immune cells. Interleukin-6 (IL-6) is a crucial regulator of T cells and is increased in obesity. Here we report that classical IL-6 signalling in T cells promotes inflammation and insulin resistance during the first 8 weeks on a high-fat diet (HFD), but becomes dispensable at later stages (after 16 weeks). Mice with T cell-specific deficiency of IL-6 receptor-α (IL-6RαT-KO) exposed to a HFD display improved glucose tolerance, insulin sensitivity and inflammation in liver and EWAT after 8 weeks. However, after 16 weeks, insulin resistance in IL-6RαT-KO epididymal white adipose tissue (EW…

Blood GlucoseMale0301 basic medicinemedicine.medical_specialtyTime FactorsT-LymphocytesT cellScienceGeneral Physics and AstronomyInflammationWhite adipose tissueBiologyDiet High-FatArticleGeneral Biochemistry Genetics and Molecular BiologyMice03 medical and health sciences0302 clinical medicineInsulin resistanceImmune systemInternal medicinemedicineAnimalsHomeostasisObesityReceptorInflammationMice KnockoutMultidisciplinaryInterleukin-6QGeneral ChemistryT lymphocyteLipid Metabolismmedicine.diseaseReceptors Interleukin-6030104 developmental biologymedicine.anatomical_structureEndocrinology030220 oncology & carcinogenesisInsulin Resistancemedicine.symptomHomeostasisSignal TransductionNature Communications
researchProduct

ERK1 and ERK2 activation modulates diet-induced obesity in mice

2017

IF 3.112; International audience; Obesity is a worldwide problem, and dietary lipids play an important role in its pathogenesis. Recently, Erk1 knock-out (ERK1(-/-)) mice have been shown to exhibit low preference for dietary fatty acids. Hence, we maintained Erk1(-/-) mice on a high-fat diet (HFD) to assess the implication of this mitogen-activated protein (MAP) kinase in obesity. The Erk1(-/-) mice, fed the HFD, were more obese than wild-type (WT) animals, fed the same diet. Erk1(-/-) obese mice gained more fat and liver mass than WT obese animals. No difference was observed in daily food and energy intake in HFD-fed both group of animals. However, feed efficiency was higher in Erk1(-/-) t…

Blood GlucoseMale0301 basic medicinemedicine.medical_treatmentMice ObeseBiochemistryMicechemistry.chemical_compoundPhosphorylationBeta oxidationCells CulturedMice KnockoutMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Reverse Transcriptase Polymerase Chain ReactionGeneral MedicineLipidsFatty acid synthaseLiverLipogenesisHomeostatic model assessmentmedicine.medical_specialtyBlotting WesternBiologyDiet High-FatReal-Time Polymerase Chain Reaction03 medical and health sciencesInsulin resistanceInternal medicinemedicineAnimals[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyRNA MessengerObesity[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyInflammationTriglycerideLipogenesisInsulinBody WeightLipid Metabolismmedicine.diseaseObesityMice Inbred C57BL030104 developmental biologyEndocrinologychemistrybiology.proteinMAP kinaseInsulin ResistanceBiochimie
researchProduct

Transgenerational effects on intestinal inflammation status in mice perinatally exposed to bisphenol S

2020

International audience; Increasing evidence has highlighted the critical role of early life environment in shaping the future health outcomes of individuals in subsequent generations. Bisphenol S (BPS) has been widely used as a substitute for various plastic materials due to the limited application of Bisphenol A (BPA) which is an endocrine disruptor. However, the lack of efficient evaluation of BPS leaves doubts about the relevant substitute of BPA. Few studies of transgenerational inheritance have examined the effects of environmental exposures to endocrine disruptors on the immune system. In this study, we analyzed the transgenerational effects of BPS on intestinal inflammation and its c…

Blood GlucoseMaleBisphenol SHealth Toxicology and Mutagenesis[SDV]Life Sciences [q-bio]0208 environmental biotechnologyPhysiology02 engineering and technologyEndocrine Disruptors010501 environmental sciences01 natural sciencesFecesMicePregnancySulfonesPerinatal ExposureGeneral MedicinePollutionIntestine[SDV] Life Sciences [q-bio][SDV.TOX] Life Sciences [q-bio]/ToxicologyIntestinesEndocrine disruptorPrenatal Exposure Delayed Effects[SDV.TOX]Life Sciences [q-bio]/ToxicologyCytokinesGestationFemalemedicine.symptomhormones hormone substitutes and hormone antagonistsEnvironmental EngineeringOffspringInflammationImmune systemPhenolsmedicineAnimalsEnvironmental ChemistryWeaningEndocrine system0105 earth and related environmental sciencesInflammationbusiness.industryBody WeightPublic Health Environmental and Occupational HealthGeneral Chemistry020801 environmental engineeringPerinatal exposureMice Inbred C57BLMetabolismbusiness
researchProduct

Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.

2021

Background and aims: To evaluate the change in circulating serum irisin and interleukin-6 (IL-6), in patients with type 2 diabetes mellitus (T2DM) after 6 and 12 months of GLP-1 treatment. Methods and results: Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment. After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase in s…

Blood GlucoseMaleIrisinmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRecombinant Fusion ProteinsGlucagon-Like PeptidesMedicine (miscellaneous)IncretinsGlucagon-Like Peptide-1 ReceptorSettore MED/13 - EndocrinologiaProinflammatory cytokineAdipokineInternal medicineMyokinemedicineHumansHypoglycemic AgentsInsulinIn patientDulaglutideGlucagon-like peptide 1 receptorAgedNutrition and DieteticsLiraglutidebusiness.industryInterleukin-6InsulinType 2 Diabetes MellitusLiraglutideMiddle AgedFibronectinsImmunoglobulin Fc FragmentsSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaEndocrinologyCholesterolTreatment OutcomeDiabetes Mellitus Type 2DulaglutideDrug Therapy CombinationFemaleInflammation MediatorsWaist CircumferenceCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

The role of morbid obesity in the promotion of metabolic disruptions and non-alcoholic steatohepatitis by Helicobacter Pylori

2016

Background Helicobacter pylory (HP) infection has been associated to an increased rate of type 2 diabetes (T2D) and liver disease through its effect on insulin resistance and systemic inflammation. However, results are inconstant and no studies exist in morbidly obese patients, in which both insulin resistance and inflammation coexist. Material and methods Cross-sectional study to evaluate the relationship between HP infection and alterations in carbohydrate metabolism, lipid profile, inflammation markers, and liver disease in patients awaiting for bariatric surgery. HP infection was histologically assessed in gastric antrum biopsy from 416 subjects. Liver biopsy was also available in 93 su…

Blood GlucoseMalePhysiologyBiopsylcsh:MedicineType 2 diabetesPathology and Laboratory MedicineBiochemistryGastroenterologyLiver diseaseEndocrinology0302 clinical medicineNon-alcoholic Fatty Liver DiseaseMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceImmune ResponseMultidisciplinarymedicine.diagnostic_testLiver DiseasesFatty liverMiddle AgedObesity MorbidPhysiological ParametersLiver biopsyCarbohydrate MetabolismFemale030211 gastroenterology & hepatologyResearch ArticleAdultmedicine.medical_specialtyEndocrine DisordersImmunologySurgical and Invasive Medical ProceduresGastroenterology and HepatologyHelicobacter Infections03 medical and health sciencesSigns and SymptomsInsulin resistanceDiagnostic MedicineInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumansObesityInflammationHelicobacter pyloriEndocrine Physiologybusiness.industryBody Weightlcsh:RBiology and Life Sciencesmedicine.diseaseImpaired fasting glucoseMorbid ObesityFatty LiverCross-Sectional StudiesMetabolismEndocrinologyDiabetes Mellitus Type 2Metabolic Disorderslcsh:QInsulin ResistanceSteatohepatitisbusiness
researchProduct

Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response

2000

Objectives: The aim of the present study was to evaluate the effects of pravastatin treatment on lipid, inflammation, and coagulation parameters in patients suffering from myocardial infarction with or without carotid atherosclerotic lesions (groups 1 and 2, respectively). Methods: In the first phase of the study, a cross-sectional comparison of lipid, inflammation, and coagulation parameters was performed between the patients and the control group (group 3). Highly significant differences in these parameters were observed, especially in group 1. In the second phase of the study, we assessed the effects of a persistent reduction in cholesterol synthesis induced by increasing doses of pravas…

Blood GlucoseMalemedicine.medical_specialtyMyocardial InfarctionInflammationCoronary Artery DiseaseFibrinogenchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumansPharmacology (medical)PravastatinInflammationPharmacologyDose-Response Relationship DrugFactor VIIbusiness.industryCholesterolpravastatin inflammatory responseGeneral MedicineMiddle AgedBlood Coagulation FactorsCholesterolCross-Sectional StudiesEndocrinologyCoagulationchemistryCase-Control StudiesHemostasisFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptombusinessPravastatinmedicine.drugLipoproteinEuropean Journal of Clinical Pharmacology
researchProduct

Protein oxidation in a group of subjects with metabolic syndrome.

2013

Abstract Aims To examine the protein oxidation, marker of the oxidative stress, in metabolic syndrome (MS). Methods We enrolled 106 subjects (45 women and 61 men) with MS of which 43 (14 women and 27 men) were with diabetes mellitus and 63 (31 women and 32 men) were without diabetes mellitus, and 54 subjects (19 women and 35 men) as control group. The protein oxidation, expressed as carbonyl groups, was measured by an enzyme-like immunosorbent assay (ELISA) kit (BioCell PC test kit, Enzo Life Sciences AG, Switzerland). Results In the whole group of MS subjects, in comparison with control group, a significant increase in carbonyl groups was present. The same datum was also evident between co…

Blood GlucoseMalemedicine.medical_specialtyWaistEndocrinology Diabetes and MetabolismIndiaBlood PressureProtein oxidationmedicine.disease_causeNitric OxideProtein CarbonylationInternal medicineDiabetes mellitusinsulin resistanceInternal MedicinemedicineHumansInflammationMetabolic Syndromeoxidative strebusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseOxidative StressEndocrinologyBlood pressureDiabetes Mellitus Type 2FemaleMetabolic syndromeWaist CircumferencebusinessOxidation-ReductionOxidative stressBiomarkersDiabetesmetabolic syndrome
researchProduct

Eicosapentaenoic acid modulates fatty acid metabolism and inflammation in Psammomys obesus.

2015

Abstract The desert gerbil, Psammomys obesus, is a unique polygenic animal model of metabolic syndrome (insulin resistance, obesity and type 2 diabetes), and these pathological conditions resemble to those in human beings. In this study, the animals were fed ad libitum either a natural diet (ND) which contained desertic halophile plants or a standard laboratory diet (STD) or a diet which contained eicosapentaenoic acid (EPA), hence, termed as EPA diet (EPAD). In EPAD, 50% of total lipid content was replaced by EPA oil. By employing real-time PCR, we assessed liver expression of key genes involved in fatty acid metabolism such as PPAR-α, SREBP-1c, LXR-α and CHREBP. We also studied the expres…

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentInterleukin-1betaAdipose tissueGene ExpressionBiologyBiochemistrychemistry.chemical_compoundInsulin resistanceInternal medicinemedicineAnimalsInsulinPPAR alphaRNA MessengerTriglyceridesLiver X Receptorschemistry.chemical_classificationFatty acid metabolismReverse Transcriptase Polymerase Chain ReactionTumor Necrosis Factor-alphaInsulinBody WeightFatty AcidsGeneral Medicinebiology.organism_classificationmedicine.diseaseLipid MetabolismOrphan Nuclear ReceptorsEicosapentaenoic acidEndocrinologychemistryAdipose TissueEicosapentaenoic AcidLiverlipids (amino acids peptides and proteins)PsammomysMetabolic syndromeInflammation MediatorsGerbillinaeSterol Regulatory Element Binding Protein 1Polyunsaturated fatty acidBiochimie
researchProduct

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model b…

2014

Objective In diabetes, vascular dysfunction is characterized by impaired endothelial function due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion. The aim of the present study was to test whether treatment with empagliflozin improves endothelial dysfunction in type I diabetic rats via reduction of glucotoxicity and associated vascular oxidative stress. Methods Type I diabetes in Wistar rats was induced by an intravenous injection of streptozotocin (60 mg/kg). One week after injection empagliflozin (10 and 30 mg/kg/d) was adminis…

Blood GlucoseMalemedicine.medical_treatmentReceptor for Advanced Glycation End Productslcsh:MedicineGene ExpressionType 2 diabetesmedicine.disease_causeVascular MedicineGlucosidesMedicine and Health SciencesMedicineInsulinEndothelial dysfunctionReceptors Immunologiclcsh:ScienceMultidisciplinaryType 1 DiabetesCytokinesInflammation Mediatorsmedicine.drugSignal TransductionResearch Articlemedicine.medical_specialtyCardiologyBlood sugarStreptozocinCardiovascular PharmacologyDiabetes Mellitus ExperimentalDiabetes ComplicationsInternal medicineDiabetes mellitusEmpagliflozinDiabetes MellitusAnimalsRNA MessengerVascular DiseasesBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsPharmacologybusiness.industryInsulinlcsh:RHemodynamicsStreptozotocinmedicine.diseaseRatsOxidative StressEndocrinologyGlucoseMetabolic Disorderslcsh:QbusinessOxidative stressDiabetic AngiopathiesPloS one
researchProduct